Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.

Lee JC, Chou LC, Lien JC, Wu JC, Huang CH, Chung CH, Lee FY, Huang LJ, Kuo SC, Way TD.

Oncol Rep. 2013 Oct;30(4):1762-72. doi: 10.3892/or.2013.2634. Epub 2013 Jul 23.


Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.


Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.

Oncogene. 1999 Apr 1;18(13):2241-51.


Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.

Cancer Res. 2002 Oct 15;62(20):5703-10.


Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.


Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J.

Cancer Res. 1998 Jul 1;58(13):2825-31. Erratum in: Cancer Res 1999 Apr 15;59(8):2020.


In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.

Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.

Cancer Immunol Immunother. 2011 Mar;60(3):339-48. doi: 10.1007/s00262-010-0937-7. Epub 2010 Nov 18.


Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.

Seoane S, Montero JC, Ocaña A, Pandiella A.

J Natl Cancer Inst. 2010 Sep 22;102(18):1432-46. doi: 10.1093/jnci/djq315. Epub 2010 Sep 1.


HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.


Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.

Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD.

Pharm Res. 2007 Dec;24(12):2402-11. Epub 2007 Sep 9.


Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8.


Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N.

Cancer Res. 2003 May 1;63(9):2139-44.


The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.


Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.

Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182. Epub 2012 Oct 11.


Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.

Luistro LL, Rosinski JA, Bian H, Bishayee S, Rameshwar P, Ponzio NM, Ritland SR.

Int J Oncol. 2012 Aug;41(2):639-51. doi: 10.3892/ijo.2012.1463. Epub 2012 May 8.


Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.


Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells.

Lien JC, Hung CM, Lin YJ, Lin HC, Ko TC, Tseng LC, Kuo SC, Ho CT, Lee JC, Way TD.

Chem Biol Interact. 2015 Jun 25;235:17-26. doi: 10.1016/j.cbi.2015.04.005. Epub 2015 Apr 10.


Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.

Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M.

Mol Cancer Ther. 2006 Feb;5(2):317-28.

Supplemental Content

Support Center